Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (5279)	8/27/1998 10:06:00 PM
From: HiSpeed	Respond to of 9523

Good article; thanx for posting! One key item that caught my attention: "Boasting double-digit earnings growth of 15%-20%, compared with 5%-10% for the S&P 500 Index, drug companies remain fundamentally strong, making investors flock to them in uncertainty." Isn't the double digit growth (or the expectations of) a key that has been an underlying fundamental of the bull market of the past few years? Now that earnings are only in the single digits, the market is correcting accordingly. However, if the Drug companies continue to post double digit growth, does it stand to reason that the ADRs of these companies continue to ramp? I'm sure there is more to it than this (JMO). Any other thoughts would be appreciated....